Market news
Grace Therapeutics (GRCE) filed a registration statement Monday with the US Securities and Exchange
Detailed price information for Grace Therapeutics Inc (GRCE-Q) from The Globe and Mail including charting and trades.
Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028PRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “the Company”), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that it has entered into a securities purchase
This is the newest page. Registered accounts read further back.